3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Breast
4
Thoracic
3
Genitourinary
3
Other solid neoplasm
2
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Endocrine
1
Conditions
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
Stomach Neoplasms
1
Sarcoma
1
Neoplasm Metastasis
1
Mesothelioma, Malignant
1
Gastro-enteropancreatic neuroendocrine tumor
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Biliary Tract Neoplasms
1
Interventions
lutetium Lu 177 dotatate
32
Everolimus
19
Magnetic Resonance Spectroscopy
14
gallium Ga 68 dotatate
12
Temozolomide
12
Nivolumab
11
Capecitabine
10
pembrolizumab
9
lanreotide
9
cabozantinib
8
Positron Emission Tomography Computed Tomography
8
177Lu-octreotide, DOTA(0)-Tyr(3)-
8
Ga(III)-DOTATOC
7
3-Iodobenzylguanidine
7
Somatostatin
6
Octreotide
6
Lutetium-177
6
Carboplatin
6
90Y-octreotide, DOTA-Tyr(3)-
6
telotristat ethyl
5
surufatinib
5
lenvatinib
5
Ipilimumab
5
Fluorodeoxyglucose F18
5
pasireotide
4
copper dotatate CU-64
4
avelumab
4
Single Photon Emission Computed Tomography Computed Tomography
4
Positron-Emission Tomography
4
Bevacizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Clinical Trials, Phase II as Topic
×
NET
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled